In a retrospective analysis of the GOG-0218 trial, a modelled CA-125 ELIMination rate constant K (#KELIM) could identify patients who have the highest benefit from #bevacizumab as first line treatment in patients with advanced #ovarian_cancer.

In this analysis, patients’ KELIM scores were calculated using CA-125 kinetics during the first 100 chemotherapy days and calculated using mathematical modelling).This was further validated based on data from more than 12,000 patients in 12 randomised trials.

An unfavourable #KELIM score (< 1.0) was associated with bevacizumab benefit compared with placebo (PFS: HR, 0.70; 95% CI, 0.59 to 0.82; OS: HR, 0.87; 95% CI, 0.73 to 1.03), whereas a favourable KELIM (≥ 1.0) was not.